In our preclinical studies, using NSCLC cell lines, which carry the LUAD‐relevant KRAS and EGFR mutations, HCI‐2509 inhibited cell growth in the IC50 range 1–5 μm as measured by cell‐based assays. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.